ORG – Page 257 – Talk Bio

AltruBio Secures $225M for Midphase Ulcerative Colitis Program Following Checkpoint Drug Modification

1 year ago talkbio0Tagged AltruBio, Biotechnology, checkpoint drug, Drug Development, healthcare innovation, midphase, midphase program, Ulcerative Colitis

AltruBio, checkpoint drug, ulcerative colitis, $225M funding, midphase program, biotechnology, drug development, healthcare innovation.

Extended Data from Gilead’s PBC Program Strengthens Case Ahead of FDA Ruling

1 year ago talkbio0Tagged Biliary Cholangitis, Decision, Gilead, Long-term, Primary Biliary Cholangitis, Programs - Publication Format, United States Food and Drug Administration

Gilead, PBC Program, FDA Decision, Long-term Data, Primary Biliary Cholangitis

Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment

1 year ago talkbio0Tagged Disease remission, Effectiveness, guselkumab, Inflammatory Bowel Diseases, J&J, Johnson & Johnson, Maintenance, Phase 3 Clinical Trials, Safety, Tremfya, Ulcerative Colitis

J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.

EU Upholds Approval of PTC Therapeutics’ Duchenne Muscular Dystrophy Treatment

1 year ago talkbio0Tagged Approved, Duchenne, EU, factor IX, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Rejection (Psychology)

EU, PTC Therapeutics, Duchenne Muscular Dystrophy (DMD), treatment, approval, rejection, committee.

Hims & Hers Expands Weight-Loss Solutions with GLP-1 Injections

1 year ago talkbio0Tagged Glucagon-Like Peptide 1, Hims & Hers, Injection of therapeutic agent, metabolic health, Obesity, Prescription procedure, Telemedicine, Weight-Loss

Hims & Hers, GLP-1 injections, weight-loss, telehealth, prescription medication, obesity treatment, metabolic health

Translarna by PTC Therapeutics: Awaiting Another EU Regulatory Review for Muscular Dystrophy Treatment

1 year ago talkbio0Tagged ataluren, disease treatment, EU, European Medicines Agency, factor IX, Infrequent, Muscular Dystrophy, Muscular Dystrophy, Duchenne, regulatory approval, Translarna

PTC Therapeutics, Translarna, muscular dystrophy, EU review, regulatory approval, Duchenne muscular dystrophy (DMD), European Medicines Agency (EMA), ataluren, rare disease treatment.

FDA Revokes Accelerated Approval of Helsinn’s Cancer Drug at Company’s Request

1 year ago talkbio0Tagged Accelerated, Antineoplastic Agents, Approved, Clinical Trials, Helsinn, patient safety, regulatory, United States Food and Drug Administration

FDA, Helsinn, accelerated approval, cancer drug, company request, drug withdrawal, regulatory decision, clinical trials, patient safety.

Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine

1 year ago talkbio0Tagged BioNTech, COVID19 (disease), Drug Industry, EPO, EU, European (ethnic group), Intellectual Property, Legal patent, Moderna, mRNA technology, Pfizer, Vaccines

Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.